HCA Healthcare, Inc.
HCA Healthcare, Inc. is classed by the SEC under Services-General Medical & Surgical Hospitals, NEC (industry code 8062), based in Nashville, TN. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $76 billion and a profit of $6.8 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8062, Services-General Medical & Surgical Hospitals, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.3 out of ten, 9 of 9 metrics filed: past 7.5 out of ten, present 6.6 out of ten, future 4.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 7.3 out of ten. No warning events in its filings since 2017. 73rd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 6.8 out of ten. +6.7% a year over 7 filed years; profitable in 7 of 7. 68th percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 9.3 out of ten. Share count shrank 6.7% a year. 67% of cash flow returned. Insiders: 13 sales, 0 purchases. 93rd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 5.2 out of ten. Leverage 105%: owes 105¢ per asset dollar. 52nd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.3 out of ten. top 27% of 22 in its family; net margin 9%. 73rd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 7.0 out of ten. top 30% of 19 in its family for leadership; chief executive since 2019. 70th percentile among 19 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.6 out of ten. bottom 46% of 22 in its family for room to expand. 46th percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 4.7 out of ten. bottom 47% of 22 in its family for growth drivers. 47th percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 4.3 out of ten. bottom 43% of 22 in its family for expectations against reality. 43rd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-10 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-28 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-24 (on EDGAR). Newest filing: Form 3, 2026-09-11. Filings on record since 1994. Read from EDGAR 2026-10-12.
Who runs it
Hazen, Samuel N (CEO); Marks, Mike A (EVP and CFO); Foster, Jon M (EVP and COO); Schlosser, Michael J (EVP and Chief Clinical Officer); Mcalevey, Michael R (EVP & Chief Legal & Admin Off.); Berres, Jennifer (SVP & Chief Human Res. Officer); Cuffe, Michael S. (EVP and Chief Clinical Officer); Rossitto, Erica (SVP & Chief Nurse Executive); Wyatt, Christopher F. (SVP & Controller); Chidsey, John (director); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.